Author

Jennie Rachel Lance

Observed names: J Rachel Lance, J. Rachel Lance, Jennie R. Lance, Lance, Jennie R

Observed institutions: Hendrix College, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

OpenAlex ID: A5012360144

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML

2023 · Sheng F. Cai, Ying Huang, et al. · Blood Advances · 24

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy

2022 · Max Yano, Chia Sharpe, et al. · Blood Advances · 13

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

2019 · Max Yano, Jennie Rachel Lance, et al. · Blood · 1

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

2019 · Jennie Rachel Lance, Max Yano, et al. · Blood · 1

Evaluation of membrane bound IL-21 expanded natural killer cells for chronic lymphocytic leukemia therapy

2021 · Max Yano, J Rachel Lance, et al. · The Journal of Immunology

Works count: 6

Citation count: 42

H-index: 3

I10-index: 2